Published in Lab Business Week, January 8th, 2006
"The investment by the MIG funds provides substantial funding of our advanced clinical program designed to obtain approval of our antisense drug, AP 12009, which we are developing for patients with malignant tumors including brain tumors and pancreatic cancer," explained Reimar Schlingensiepen, founder and COO of Antisense Pharma.
The company has repeatedly received prestigious awards for the innovative potential and goal-directed drug development program as well as corporate management. The lead drug candidate AP 12009 is targeted against...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week